BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN BEGIN:VTIMEZONE TZID:GMT Standard Time BEGIN:STANDARD DTSTART:20251002T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=10 TZNAME:GMT Standard Time TZOFFSETFROM:+0100 TZOFFSETTO:+0000 END:STANDARD BEGIN:DAYLIGHT DTSTART:20250301T010000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=1;BYMINUTE=0;BYMONTH=3 TZNAME:GMT Daylight Time TZOFFSETFROM:+0000 TZOFFSETTO:+0100 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:Date: \;Thursday 10th December 2020\nTime: \;15:00 - 16 :00 GMT\nSpeaker: \;Scott Patterson \;(Sanofi)\n\nWho is this even t intended for? \;Statisticians interested in the statistics of crisis vaccine clinical studies\, like those being done for COVID-19.\nWhat is t he benefit of attending? \;Those attending will learn of several stati stical observations on crisis vaccine clinical development that are import ant to an understanding of data generated in COVID-19 vaccine development and other crisis clinical vaccine programs.\nRegistration\nYou can now reg ister for this event. Registration will close at 12:00 on 9th December 202 0.\nThis event is \;free of charge \;to both Members and Non Membe rs of PSI.\nTo register your place\, please \;click here.\nOverview\nS cott Patterson\, Bo Fu\, Ya Meng\, Fabrice Bailleux\, Josh Chen. \; \n Statistical Observations on SARS-CoV-2 &\; Crisis Vaccine Clinical Test ing. \nTraditional vaccine clinical development is an undertaking involvin g meticulous\, multiple studies in multiple populations at risk of infecti on and disease over multiple years. SARS-CoV-2 and COVID-19 vaccine develo pment is following this traditional development pathway\, but accelerated Phase I-II-III clinical programs are being applied (c.f.\, USA FDA guidanc es 2020). This is not the first time vaccines have been manufactured and t ested quickly to meet a public health crisis (1976\, 2009). Selected stati stical concepts pertaining to vaccine efficacy and safety\, relevant durin g the design and implementation of such crisis programs\, will be discusse d.\nSpeaker Details\n\n\n\n \n \n \n Speak er\n \n \n Biography\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Scott Patterson\n (Sanofi)\n \n \n Scott Patterson PhD\, PStat is curre ntly the head of Statistical Innovation at Sanofi Pasteur\, the vaccines&r squo\; division of Sanofi. He and co-author Professor Byron Jones wrote `B ioequivalence and Statistics in Clinical Pharmacology&rsquo\; now in its s econd edition. Scott has over 25 years of professional experience in biost atistics\, and he and his family reside in Pennsylvania\, USA.\n \n \n \n\n \; DTEND:20201210T160000Z DTSTAMP:20260913T045654Z DTSTART:20201210T150000Z LOCATION: SEQUENCE:0 SUMMARY:PSI Vaccine SIG Webinar: Some considerations on developing COVID-19 Vaccines UID:RFCALITEM639248722140283819 X-ALT-DESC;FMTTYPE=text/html:Date: \;Thursday 10th Dec ember 2020
\nTime: \;15:00 - 16:00 GMT
\nSpeaker: \;Scott Patterson \;(Sanofi)
\n\nWho is this event intended for? \;Statisti cians interested in the statistics of crisis vaccine clinical studies\, li ke those being done for COVID-19.
\nWhat is the benefit of at tending? \;Those attending will learn of several statistical observations on crisis vaccine clinical development that are important to an understanding of data generated in COVID-19 vaccine development and oth er crisis clinical vaccine programs.
\n
Registration
\n
You can now register for this event. Registration will close at 12:00 on 9th D ecember 2020.
\nThis event is \;free of charge&n bsp\;to both Members and Non Members of PSI.
\nTo register your place \, please \;click here.
\n
Overview
\n
Scott Patterson\, Bo Fu\, Ya Meng \, Fabrice Bailleux\, Josh Chen. \;
\nStatistical Observations o n SARS-CoV-2 &\; Crisis Vaccine Clinical Testing.
\nTraditio nal vaccine clinical development is an undertaking involving meticulous\, multiple studies in multiple populations at risk of infection and disease over multiple years. SARS-CoV-2 and COVID-19 vaccine development is follow ing this traditional development pathway\, but accelerated Phase I-II-III clinical programs are being applied (c.f.\, USA FDA guidances 2020). This is not the first time vaccines have been manufactured and tested quickly t o meet a public health crisis (1976\, 2009). Selected statistical concepts pertaining to vaccine efficacy and safety\, relevant during the design an d implementation of such crisis programs\, will be discussed.
\n
Spe aker Details
\n\n\n
\n \n \n \n \n \n \n \n \n \n \n\n
\;
END:VEVENT END:VCALENDAR
\n
Speaker
\n \n
Biography
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n Scott Pa tterson
\n (Sanofi)
\n \n
Scott Patt erson PhD\, PStat is currently the head of Statistical Innovation at Sanof i Pasteur\, the vaccines&rsquo\; division of Sanofi. He and co-author Prof essor Byron Jones wrote `Bioequivalence and Statistics in Clinical Pharmac ology&rsquo\; now in its second edition. Scott has over 25 years of profes sional experience in biostatistics\, and he and his family reside in Penns ylvania\, USA.
\n

\n Speaker \n	\n Biography \n
\n \n \n \n \n \n \n \n \n \n \n Scott Pa tterson \n (Sanofi) \n	\n Scott Patt erson PhD\, PStat is currently the head of Statistical Innovation at Sanof i Pasteur\, the vaccines&rsquo\; division of Sanofi. He and co-author Prof essor Byron Jones wrote `Bioequivalence and Statistics in Clinical Pharmac ology&rsquo\; now in its second edition. Scott has over 25 years of profes sional experience in biostatistics\, and he and his family reside in Penns ylvania\, USA. \n